Edward Friedmann
Medical · Redfield, IANPI 1821006990
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 84 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $698, 3.5 times the $200 reported in 2021.
Across 84 payments — averaging $24.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$449
- Pfizer$248
- Lilly USA, LLC$243
- Boehringer Ingelheim$234
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$195
- AstraZeneca$180
- plus $500 from 8 others
What the payments were for
- Food & beverage$2,050100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 16 | $449 |
| Pfizer | 10 | $248 |
| Lilly USA, LLC | 15 | $243 |
| Boehringer Ingelheim | 10 | $234 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $195 |
| AstraZeneca | 7 | $180 |
| Novo Nordisk | 9 | $167 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $139 |
| Axsome Therapeutics, Inc. | 1 | $90 |
| Idorsia Pharmaceuticals US Inc | 2 | $39 |
| GSK | 1 | $20 |
| Amgen | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$105
- VRAYLAR$100
How this compares
$2,050 in reported general payments places this provider in the 80th percentile of 141 medical providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 82 | $59,667 |
| OzempicSemaglutide | 31 | $28,630 |
| EliquisApixaban | 48 | $25,576 |
| FarxigaDapagliflozin Propanediol | 29 | $24,032 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $22,640 |
| JanuviaSitagliptin Phosphate | 17 | $13,987 |
| RybelsusSemaglutide | 12 | $11,433 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $10,261 |
| GlyxambiEmpagliflozin/Linagliptin | 12 | $7,212 |
| Varenicline Tartrate | 25 | $6,475 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $5,115 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 161 | $4,887 |
| Dexlansoprazole DrDexlansoprazole | 15 | $3,526 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,521 |
| Levothyroxine Sodium | 242 | $1,933 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi | $234 | $66,88094 claims |
| Novo NordiskOzempic, Rybelsus | $167 | $40,06343 claims |
| AstraZenecaFarxiga, Symbicort | $180 | $26,55240 claims |
| PfizerEliquis | $248 | $25,57648 claims |
| GSKTrelegy Ellipta | $20 | $10,26116 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $15 | $5,11511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 141 medical providers in Iowa.
Other medical in Redfield
- Patricia ArasonWest Des Moines$119K
- Maria SonnackIowa City$100K
- Kristin BabbAtlantic$16K
- Laura QuinnetteCouncil Bluffs$14K
- Laurie HughellUrbandale$9K
- Elizabeth McCullochWest Des Moines$6K
- Jordan GreinerPella$6K
- Samantha SmithBrooklyn$5K
- Emily EricksonDes Moines$5K
- Jennifer VandivierWest Des Moines$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.